View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCore Scientific 将来の成長Future 基準チェック /16Core Scientificは、155.2%と10.7%でそれぞれ年率155.2%で利益と収益が成長すると予測される一方、EPSはgrowで155.5%年率。主要情報155.2%収益成長率155.49%EPS成長率IT 収益成長12.7%収益成長率10.7%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日14 Jan 2023今後の成長に関する最新情報お知らせ • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.すべての更新を表示Recent updatesお知らせ • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024お知らせ • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • Jun 08CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ).CoreWeave, Inc. made an unsolicited non-binding proposal to acquire Core Scientific, Inc. (NasdaqGS:CORZ) for $1.2 billion on June 3, 2024. CoreWeave made a proposal to acquire all of the outstanding shares of Core Scientific on a fully diluted basis for $5.75 per share in cash. The Board of Directors of Core Scientific determined that the CoreWeave proposal significantly undervalues the Company and is not in the best interests of Core Scientific and its shareholders. Moelis & Company LLC is acting as financial advisor to Core Scientific. Sidley Austin LLP is acting as legal advisor to Core Scientific. CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ) on June 6, 2024.お知らせ • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024お知らせ • Jan 25+ 1 more updateCore Scientific, Inc. Emerged from BankruptcyCore Scientific, Inc. emerged from its Chapter 11 bankruptcy as its modified fourth amended plan of reorganization became effective on January 23, 2024. Core Scientific, Inc. had filed its modified fourth amended plan of reorganization in the Court on January 15, 2024.お知らせ • Jan 24+ 1 more updateCore Scientific, Inc. Com Deleted from OTC EquityCore Scientific, Inc. Com has been deleted from OTC Equity effective January 23, 2024, due to Bankruptcy Plan Effective Shares Cancelled /Distribution.お知らせ • Jan 18Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.The US Bankruptcy Court approved the modified fourth amended joint plan of reorganization and Disclosure Statement of Core Scientific, Inc. on January 16, 2024. The debtor has filed its modified fourth amended joint plan in the Court on January 15, 2024. As per the amended plan, administrative expense claims, professional fee claims, priority non-tax claim, priority tax claims, DIP claims of $105 million, shall be paid in full in cash. April convertible notes secured claims of $350 million shall receive its pro rata share of the new secured notes, pro rata reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (iii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iv) such holder’s pro rata total convertible notes. August convertible notes secured claims of $360 million shall receive its pro rata share of reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (ii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iii) such holder’s pro rata total convertible notes share of (a) the ERO shortfall equity distribution (if any), (b) the first incremental convertible noteholders equity distribution (if any), and (c) the second incremental convertible noteholders equity distribution. Miner equipment lender secured claims of $253.7 million shall receive such holder’s applicable miner equipment lender takeback debt. Other secured claims of $20.6 million shall be reinstated. M&M lien secured claims are of $0. Secured mortgage claims of $0.81 million shall receive such Holder’s applicable Mortgage Takeback Debt. General unsecured claims of $89.6 million shall receive its pro rata share of new common interests with a value, based on plan value, equal 100% of such holder’s allowed general unsecured claim, (y) such holder’s pro rata share of the GUC settlement additional equity distribution amount, and (z) such holder’s pro rata share of the GUC contingent payment obligations. Convenience claims of $0.13 million shall be paid in full in cash. Intercompany claims and intercompany interests shall be reinstated. Section 510(b) claims are estimated to be $0. Existing common interests shall receive its pro rata share of equity share of the residual equity pool, (ii) such holder’s pro rata equity share of the new warrants, and (iii) the right to participate in the rights offering in accordance with the rights offering procedures. The plan shall be funded through cash, new April secured notes, new August secured notes, first-lien delayed draw term loans, M&M lien takeback debt, miner equipment lender takeback debt, mortgage takeback debt, and common stock.お知らせ • Jan 09Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Dec 28Amended Reorganization Plan Filed by Core Scientific, Inc.Core Scientific, Inc., along with its affiliates, filed fourth amended joint plan of reorganization with related disclosure statement in the US Bankruptcy Court on December 26, 2023. As per the plan filed, Convenience Claims shall be paid in cash.お知らせ • Nov 22Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Sep 23Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies LimitedCore Scientific, Inc. announced a private placement of common shares for the gross proceeds of $53.9 million on September 22, 2023. The transaction will include participation from new investor Bitmain Technologies Limited.お知らせ • Aug 05Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive OfficerCore Scientific, Inc. announced Adam Sullivan has been appointed Chief Executive Officer. Adam assumes the CEO position after serving as President of Core Scientific. Mike Levitt will continue as the Chairman of the Board of Directors. Since joining the company, Adam has redesigned Cores organizational structure, enhanced the Companys restructuring efforts and improved communication and collaboration across functions. Adams expertise and strategic vision for the future of Core Scientific has resulted in increased engagement across the team. Adam Sullivan has more than a decade of experience in financial services, with a focus on investment banking in the digital assets and infrastructure space. His expertise spans strategy development, corporate finance and M&A. Prior to joining Core Scientific as President in 2023, Adam served as a Managing Director and Head of Digital Assets and Infrastructure at XMS Capital Partners. In his role at XMS, Adam established himself as one of the key facilitators for M&A and capital raises in the crypto mining industry, overseeing more than $5 billion of transactions, including Core Scientifics business combination with Power &Digital Infrastructure Acquisition Corp. in 2021. He previously served at Indian Wells Capital Management and M&T Bank. Adam received his Bachelor of Arts in Financial Economics from the University of Rochester.お知らせ • May 18Core Scientific, Inc. Appoints Adam Sullivan as PresidentOn April 20, 2023, the board of directors of Core Scientific, Inc. appointed Adam Sullivan as president, effective May 15, 2023. Mr. Sullivan will report to Mike Levitt, the Company’s Chief Executive Officer, and will oversee financial and strategic matters, including assisting with the negotiation of the Company’s reorganization plan. In connection with the appointment of Mr. Sullivan, Todd M. DuChene will continue to serve as the Company’s Chief Legal Officer while also assuming the new role of Chief Administrative Officer. Prior to his appointment as President, Mr. Sullivan, age 32, was Managing Director and Head of Digital Assets and Infrastructure Group at XMS Capital Partners, where he oversaw over $5 billion of transactions. Mr. Sullivan joined XMS Capital Partners in 2017. Mr. Sullivan also represented the Power and Digital Infrastructure Acquisition Corporation in its acquisition of Core Scientific Holding Company, the Company’s predecessor, in 2021.お知らせ • May 11Core Scientific, Inc. announced delayed 10-Q filingOn 05/10/2023, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 04Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite IndexCore Scientific, Inc. has been removed from NASDAQ Composite Index .お知らせ • Dec 28Core Scientific's Common Stock to Be Delisted from NasdaqOn December 22, 2022, Core Scientific, Inc. received written notice (the "Delisting Notice") from the staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company's common stock (the "Securities") will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on January 3, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Securities from listing and registration on Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns related to the Chapter 11 Cases. The Delisting Notice also indicates that the Company may appeal Nasdaq's determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company is currently evaluating the options available to it in connection with Delisting Notice.お知らせ • Dec 22Core Scientific, Inc. Filed for BankruptcyCore Scientific, Inc., along with its ten affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on December 21, 2022. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Alfredo R Perez of Weil, Gotshal & Manges LLP as its legal counsel. The debtor also hired PJT Partners LP as its investment banker and AlixPartners, LLP as its financial advisor. Stretto Inc. has been appointed as claims and noticing agent to the debtor.お知らせ • Dec 17Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price RequirementOn December 13, 2022, Core Scientific, Inc. ("the Company") received a written notice (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, because theclosing bid price for the Company's common stock, par value $0.0001 per share (the Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). This Notice has no immediate effect on the listing of the Company's Common Stock. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 12, 2023, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company's Common Stock does not regain compliance with the Minimum Bid Price Requirement during this initial 180-day grace period, the Company may be eligible for an additional grace period of 180 calendar days provided that (i) the Company satisfies Nasdaq's continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Bid Price Requirement; and (ii) the Company provides written notice to Nasdaq of its intention to cure the delinquency during the second grace period. The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.お知らせ • Nov 30Stacie Olivares Resigns as A Director of Core Scientific, IncOn November 21, 2022, Stacie Olivares informed the Board of Directors of Core Scientific, Inc. of her intention to resign as a director of the Board and any committees thereof effective November 21, 2022. Ms. Olivares’ resignation was not due to any disagreement with the Board, the Company or management on any matter relating to the Company's operations, policies or practices.お知らせ • Nov 16Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022On November 9, 2022, the board of directors of Core Scientific, Inc. appointed Todd DuChene to serve as the Company’s President and Chief Legal Officer, effective November 14, 2022. Mr. DuChene, age 59, has served as the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Secretary since January 2022. He had served as General Counsel and Secretary of Core Scientific Holding Co. from April 2019 until Legacy Core’s merger with Power & Digital Infrastructure Acquisition Corp. Prior to joining Legacy Core, Mr. DuChene served as Senior Vice President, General Counsel and Secretary and Chief Compliance Officer for FLIR Systems, Inc., an industrial and military technology company, from September 2014 to April 2019.お知らせ • Nov 15+ 1 more updateCore Scientific, Inc. announced delayed 10-Q filingOn 11/14/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 28+ 2 more updatesCore Scientific, Inc Contemplates BankruptcyCore Scientific, Inc is contemplating filing for bankruptcy, as of October 27, 2022. According to company press release, Company said that as it is unable to satisfy its debt obligations, it will have a material adverse effect on its financial condition and results of operations, which may result in bankruptcy or insolvency.お知らせ • Oct 27Core Scientific, Inc. Announces Management ChangesCore Scientific, Inc. announced that on October 19, 2022, the Company eliminated the position held by Brian Neville, the Company’s Controller and Chief Accounting Officer. Denise Sterling, the Company’s Executive Vice President and Chief Financial Officer, will serve as principal accounting officer, effective immediately, in addition to her existing responsibilities. Ms. Sterling has served as the Company’s Chief Financial Officer since April 4, 2022, and prior to that she served as the Company’s Senior Vice President of Finance from May 2021.お知らせ • Aug 17Core Scientific, Inc. announced delayed 10-Q filingOn 08/16/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.お知らせ • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.お知らせ • Jul 22Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLCCore Scientific, Inc. entered into a common stock purchase agreement with B. Riley Principal Capital II, LLC for gross proceeds of $100 million on July 20, 2022. The company issued purchase notices to the investor for over a 24-month period, and also issued 573,381 shares to the investor as consideration for its purchase under the purchase agreement. The company reimbursed $75,000 of reasonable legal fees and disbursements of investor's legal counsel in connection with the transactions. The securities issued will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the commission under the Securities Act.お知らせ • Jul 06Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022Core Scientific, Inc. announced that they will report Q2, 2022 results on Aug 11, 2022Recent Insider Transactions • Jun 03Co-Founder recently sold €8.4m worth of stockOn the 1st of June, Darin Feinstein sold around 3m shares on-market at roughly €3.25 per share. This was the largest sale by an insider in the last 3 months. This was Darin's only on-market trade for the last 12 months.お知らせ • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 22x in the IT industry in Germany.Reported Earnings • Apr 27Full year 2021 earnings released: EPS: US$0.36 (vs US$0.23 loss in FY 2020)Full year 2021 results: EPS: US$0.36 (up from US$0.23 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 20% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €5.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the IT industry in Germany.お知らせ • Apr 09+ 1 more updateCore Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLCCore Scientific, Inc. announced that it has entered into two bridge promissory notes with an affiliate of B. Riley Commercial Capital, LLC for gross proceeds of $75,000,000 on April 7, 2022. The two notes are in an aggregate principal amount of $60,000,000 and $15,000,000 respectively. The notes mature on December 7, 2022, bear interest at a rate of 7% per annum and amortize in equal monthly installments starting on August 1, 2022. The notes are unsecured and not guaranteed by any subsidiary of the company.お知らせ • Apr 06Core Scientific, Inc. Announces CFO ChangesCore Scientific, Inc. announced that Denise Sterling, Senior Vice President of Finance, has been appointed to the role of Chief Financial Officer and will be moving to the Austin, TX headquarters later 2022. Former CFO Michael Trzupek will leave the company to pursue new opportunities after a transition period. Denise Sterling joined Core Scientific in May 2021, built and led the Company’s Financial Planning and Analysis function and developed financial processes and procedures supporting the Company’s entry into the public equity markets.Prior to joining Core Scientific, Mrs. Sterling served as Senior Vice President of Finance and FP&A for Oportun.Reported Earnings • Mar 31Full year 2021 earnings released: EPS: US$365 (vs US$230 loss in FY 2020)Full year 2021 results: EPS: US$365 (up from US$230 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 101%, compared to a 17% growth forecast for the industry in Germany.Board Change • Mar 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Co-Founder, Co-Chairman & CEO Mike Levitt was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.業績と収益の成長予測DB:7ZD0 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024769-20N/AN/A112/31/2023748-220N/AN/A412/31/2022640-2,146-386205N/A9/30/2022821-1,651-560199N/A6/30/2022771-1,233-625206N/A3/31/2022683-426-759-76N/A12/31/202154447-116-57N/A9/30/2021266-16-294-172N/A6/30/2021163-1-178-130N/A3/31/202194-6-24-3N/A12/31/202060-23-25-24N/A12/31/201960-12-38-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7ZD0今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 7ZD0今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 7ZD0今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 7ZD0の収益 ( 10.7% ) German市場 ( 6.4% ) よりも速いペースで成長すると予測されています。高い収益成長: 7ZD0の収益 ( 10.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7ZD0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/17 09:08終値2023/01/18 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Core Scientific, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Ramsey El-AssalBarclaysGautam ChhuganiBernsteinNicholas GilesB. Riley Securities, Inc.18 その他のアナリストを表示
お知らせ • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.
お知らせ • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
お知らせ • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • Jun 08CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ).CoreWeave, Inc. made an unsolicited non-binding proposal to acquire Core Scientific, Inc. (NasdaqGS:CORZ) for $1.2 billion on June 3, 2024. CoreWeave made a proposal to acquire all of the outstanding shares of Core Scientific on a fully diluted basis for $5.75 per share in cash. The Board of Directors of Core Scientific determined that the CoreWeave proposal significantly undervalues the Company and is not in the best interests of Core Scientific and its shareholders. Moelis & Company LLC is acting as financial advisor to Core Scientific. Sidley Austin LLP is acting as legal advisor to Core Scientific. CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ) on June 6, 2024.
お知らせ • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024
お知らせ • Jan 25+ 1 more updateCore Scientific, Inc. Emerged from BankruptcyCore Scientific, Inc. emerged from its Chapter 11 bankruptcy as its modified fourth amended plan of reorganization became effective on January 23, 2024. Core Scientific, Inc. had filed its modified fourth amended plan of reorganization in the Court on January 15, 2024.
お知らせ • Jan 24+ 1 more updateCore Scientific, Inc. Com Deleted from OTC EquityCore Scientific, Inc. Com has been deleted from OTC Equity effective January 23, 2024, due to Bankruptcy Plan Effective Shares Cancelled /Distribution.
お知らせ • Jan 18Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.The US Bankruptcy Court approved the modified fourth amended joint plan of reorganization and Disclosure Statement of Core Scientific, Inc. on January 16, 2024. The debtor has filed its modified fourth amended joint plan in the Court on January 15, 2024. As per the amended plan, administrative expense claims, professional fee claims, priority non-tax claim, priority tax claims, DIP claims of $105 million, shall be paid in full in cash. April convertible notes secured claims of $350 million shall receive its pro rata share of the new secured notes, pro rata reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (iii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iv) such holder’s pro rata total convertible notes. August convertible notes secured claims of $360 million shall receive its pro rata share of reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (ii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iii) such holder’s pro rata total convertible notes share of (a) the ERO shortfall equity distribution (if any), (b) the first incremental convertible noteholders equity distribution (if any), and (c) the second incremental convertible noteholders equity distribution. Miner equipment lender secured claims of $253.7 million shall receive such holder’s applicable miner equipment lender takeback debt. Other secured claims of $20.6 million shall be reinstated. M&M lien secured claims are of $0. Secured mortgage claims of $0.81 million shall receive such Holder’s applicable Mortgage Takeback Debt. General unsecured claims of $89.6 million shall receive its pro rata share of new common interests with a value, based on plan value, equal 100% of such holder’s allowed general unsecured claim, (y) such holder’s pro rata share of the GUC settlement additional equity distribution amount, and (z) such holder’s pro rata share of the GUC contingent payment obligations. Convenience claims of $0.13 million shall be paid in full in cash. Intercompany claims and intercompany interests shall be reinstated. Section 510(b) claims are estimated to be $0. Existing common interests shall receive its pro rata share of equity share of the residual equity pool, (ii) such holder’s pro rata equity share of the new warrants, and (iii) the right to participate in the rights offering in accordance with the rights offering procedures. The plan shall be funded through cash, new April secured notes, new August secured notes, first-lien delayed draw term loans, M&M lien takeback debt, miner equipment lender takeback debt, mortgage takeback debt, and common stock.
お知らせ • Jan 09Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Dec 28Amended Reorganization Plan Filed by Core Scientific, Inc.Core Scientific, Inc., along with its affiliates, filed fourth amended joint plan of reorganization with related disclosure statement in the US Bankruptcy Court on December 26, 2023. As per the plan filed, Convenience Claims shall be paid in cash.
お知らせ • Nov 22Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Sep 23Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies LimitedCore Scientific, Inc. announced a private placement of common shares for the gross proceeds of $53.9 million on September 22, 2023. The transaction will include participation from new investor Bitmain Technologies Limited.
お知らせ • Aug 05Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive OfficerCore Scientific, Inc. announced Adam Sullivan has been appointed Chief Executive Officer. Adam assumes the CEO position after serving as President of Core Scientific. Mike Levitt will continue as the Chairman of the Board of Directors. Since joining the company, Adam has redesigned Cores organizational structure, enhanced the Companys restructuring efforts and improved communication and collaboration across functions. Adams expertise and strategic vision for the future of Core Scientific has resulted in increased engagement across the team. Adam Sullivan has more than a decade of experience in financial services, with a focus on investment banking in the digital assets and infrastructure space. His expertise spans strategy development, corporate finance and M&A. Prior to joining Core Scientific as President in 2023, Adam served as a Managing Director and Head of Digital Assets and Infrastructure at XMS Capital Partners. In his role at XMS, Adam established himself as one of the key facilitators for M&A and capital raises in the crypto mining industry, overseeing more than $5 billion of transactions, including Core Scientifics business combination with Power &Digital Infrastructure Acquisition Corp. in 2021. He previously served at Indian Wells Capital Management and M&T Bank. Adam received his Bachelor of Arts in Financial Economics from the University of Rochester.
お知らせ • May 18Core Scientific, Inc. Appoints Adam Sullivan as PresidentOn April 20, 2023, the board of directors of Core Scientific, Inc. appointed Adam Sullivan as president, effective May 15, 2023. Mr. Sullivan will report to Mike Levitt, the Company’s Chief Executive Officer, and will oversee financial and strategic matters, including assisting with the negotiation of the Company’s reorganization plan. In connection with the appointment of Mr. Sullivan, Todd M. DuChene will continue to serve as the Company’s Chief Legal Officer while also assuming the new role of Chief Administrative Officer. Prior to his appointment as President, Mr. Sullivan, age 32, was Managing Director and Head of Digital Assets and Infrastructure Group at XMS Capital Partners, where he oversaw over $5 billion of transactions. Mr. Sullivan joined XMS Capital Partners in 2017. Mr. Sullivan also represented the Power and Digital Infrastructure Acquisition Corporation in its acquisition of Core Scientific Holding Company, the Company’s predecessor, in 2021.
お知らせ • May 11Core Scientific, Inc. announced delayed 10-Q filingOn 05/10/2023, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 04Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite IndexCore Scientific, Inc. has been removed from NASDAQ Composite Index .
お知らせ • Dec 28Core Scientific's Common Stock to Be Delisted from NasdaqOn December 22, 2022, Core Scientific, Inc. received written notice (the "Delisting Notice") from the staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company's common stock (the "Securities") will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on January 3, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Securities from listing and registration on Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns related to the Chapter 11 Cases. The Delisting Notice also indicates that the Company may appeal Nasdaq's determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company is currently evaluating the options available to it in connection with Delisting Notice.
お知らせ • Dec 22Core Scientific, Inc. Filed for BankruptcyCore Scientific, Inc., along with its ten affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on December 21, 2022. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Alfredo R Perez of Weil, Gotshal & Manges LLP as its legal counsel. The debtor also hired PJT Partners LP as its investment banker and AlixPartners, LLP as its financial advisor. Stretto Inc. has been appointed as claims and noticing agent to the debtor.
お知らせ • Dec 17Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price RequirementOn December 13, 2022, Core Scientific, Inc. ("the Company") received a written notice (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, because theclosing bid price for the Company's common stock, par value $0.0001 per share (the Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). This Notice has no immediate effect on the listing of the Company's Common Stock. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 12, 2023, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company's Common Stock does not regain compliance with the Minimum Bid Price Requirement during this initial 180-day grace period, the Company may be eligible for an additional grace period of 180 calendar days provided that (i) the Company satisfies Nasdaq's continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Bid Price Requirement; and (ii) the Company provides written notice to Nasdaq of its intention to cure the delinquency during the second grace period. The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.
お知らせ • Nov 30Stacie Olivares Resigns as A Director of Core Scientific, IncOn November 21, 2022, Stacie Olivares informed the Board of Directors of Core Scientific, Inc. of her intention to resign as a director of the Board and any committees thereof effective November 21, 2022. Ms. Olivares’ resignation was not due to any disagreement with the Board, the Company or management on any matter relating to the Company's operations, policies or practices.
お知らせ • Nov 16Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022On November 9, 2022, the board of directors of Core Scientific, Inc. appointed Todd DuChene to serve as the Company’s President and Chief Legal Officer, effective November 14, 2022. Mr. DuChene, age 59, has served as the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Secretary since January 2022. He had served as General Counsel and Secretary of Core Scientific Holding Co. from April 2019 until Legacy Core’s merger with Power & Digital Infrastructure Acquisition Corp. Prior to joining Legacy Core, Mr. DuChene served as Senior Vice President, General Counsel and Secretary and Chief Compliance Officer for FLIR Systems, Inc., an industrial and military technology company, from September 2014 to April 2019.
お知らせ • Nov 15+ 1 more updateCore Scientific, Inc. announced delayed 10-Q filingOn 11/14/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 28+ 2 more updatesCore Scientific, Inc Contemplates BankruptcyCore Scientific, Inc is contemplating filing for bankruptcy, as of October 27, 2022. According to company press release, Company said that as it is unable to satisfy its debt obligations, it will have a material adverse effect on its financial condition and results of operations, which may result in bankruptcy or insolvency.
お知らせ • Oct 27Core Scientific, Inc. Announces Management ChangesCore Scientific, Inc. announced that on October 19, 2022, the Company eliminated the position held by Brian Neville, the Company’s Controller and Chief Accounting Officer. Denise Sterling, the Company’s Executive Vice President and Chief Financial Officer, will serve as principal accounting officer, effective immediately, in addition to her existing responsibilities. Ms. Sterling has served as the Company’s Chief Financial Officer since April 4, 2022, and prior to that she served as the Company’s Senior Vice President of Finance from May 2021.
お知らせ • Aug 17Core Scientific, Inc. announced delayed 10-Q filingOn 08/16/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.
お知らせ • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.
お知らせ • Jul 22Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLCCore Scientific, Inc. entered into a common stock purchase agreement with B. Riley Principal Capital II, LLC for gross proceeds of $100 million on July 20, 2022. The company issued purchase notices to the investor for over a 24-month period, and also issued 573,381 shares to the investor as consideration for its purchase under the purchase agreement. The company reimbursed $75,000 of reasonable legal fees and disbursements of investor's legal counsel in connection with the transactions. The securities issued will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the commission under the Securities Act.
お知らせ • Jul 06Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022Core Scientific, Inc. announced that they will report Q2, 2022 results on Aug 11, 2022
Recent Insider Transactions • Jun 03Co-Founder recently sold €8.4m worth of stockOn the 1st of June, Darin Feinstein sold around 3m shares on-market at roughly €3.25 per share. This was the largest sale by an insider in the last 3 months. This was Darin's only on-market trade for the last 12 months.
お知らせ • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 22x in the IT industry in Germany.
Reported Earnings • Apr 27Full year 2021 earnings released: EPS: US$0.36 (vs US$0.23 loss in FY 2020)Full year 2021 results: EPS: US$0.36 (up from US$0.23 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 20% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €5.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the IT industry in Germany.
お知らせ • Apr 09+ 1 more updateCore Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLCCore Scientific, Inc. announced that it has entered into two bridge promissory notes with an affiliate of B. Riley Commercial Capital, LLC for gross proceeds of $75,000,000 on April 7, 2022. The two notes are in an aggregate principal amount of $60,000,000 and $15,000,000 respectively. The notes mature on December 7, 2022, bear interest at a rate of 7% per annum and amortize in equal monthly installments starting on August 1, 2022. The notes are unsecured and not guaranteed by any subsidiary of the company.
お知らせ • Apr 06Core Scientific, Inc. Announces CFO ChangesCore Scientific, Inc. announced that Denise Sterling, Senior Vice President of Finance, has been appointed to the role of Chief Financial Officer and will be moving to the Austin, TX headquarters later 2022. Former CFO Michael Trzupek will leave the company to pursue new opportunities after a transition period. Denise Sterling joined Core Scientific in May 2021, built and led the Company’s Financial Planning and Analysis function and developed financial processes and procedures supporting the Company’s entry into the public equity markets.Prior to joining Core Scientific, Mrs. Sterling served as Senior Vice President of Finance and FP&A for Oportun.
Reported Earnings • Mar 31Full year 2021 earnings released: EPS: US$365 (vs US$230 loss in FY 2020)Full year 2021 results: EPS: US$365 (up from US$230 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 101%, compared to a 17% growth forecast for the industry in Germany.
Board Change • Mar 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Co-Founder, Co-Chairman & CEO Mike Levitt was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.